Disease-targeted sequencing: A cornerstone in the clinic

Nature Reviews Genetics

Volumn 14, Issue 4, 2013, Pages 295-300

  Rehm, Heidi L ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b LABORATORY FOR MOLECULAR MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; PROTEIN TYROSINE PHOSPHATASE;

CARDIOMYOPATHY; CHROMOSOME ANALYSIS; COST EFFECTIVENESS ANALYSIS; EXOME; FABRY DISEASE; GENE SEQUENCE; GENETIC SCREENING; GENETIC VARIABILITY; HEARING IMPAIRMENT; HEART VENTRICLE HYPERTROPHY; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INFECTION; MOLECULARLY TARGETED THERAPY; MUSCULAR DYSTROPHY; OTOACOUSTIC EMISSION; PATIENT CARE; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REGISTER; RETINITIS PIGMENTOSA; REVIEW; TEMPORAL BONE; TRANSLATIONAL RESEARCH;

GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; REPRODUCIBILITY OF RESULTS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84875217898     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg3463     Document Type: Review

References (32)

1. Yu, B., Sawyer, N. A., Chiu, C., Oefner, P. J. & Underhill, P. A. DNA mutation detection using denaturing high-performance liquid chromatography (DHPLC). Curr. Protoc. Hum. Genet. 48, 7.10.1-7.10.14 (2006).
2. Gowrisankar, S. et al. Evaluation of next generation sequencing of 19 dilated cardiomyopathy genes for clinical applications. J. Mol. Diagn. 12, 818-827 (2010).
3. Teekakirikul, P., Cox, S. W., Funke, B. & Rehm, H. L. Targeted sequencing using Affymetrix CustomSeq arrays. Curr. Protoc. Hum. Genet. 69, 7.18.1-7.18.17 (2011).
4. Palomaki, G. E. et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet. Med. 14, 296-305 (2012).
5. O'Sullivan, J. et al. A paradigm shift in the delivery of services for diagnosis of inherited retinal disease. J. Med. Genet. 49, 322-326 (2012).
6. Teekakirikul P., Kelly, M. A., Rehm, H. L., Lakdawala, N. K. & Funke, B. H. Inherited cardiomyopathies: molecular genetics and clinical genetic testing in the postgenomic era. J. Mol. Diagn. 27 Dec 2012 doi:10.1016/j.jmoldx. 2012.09.002.
7. Valencia, C. A. et al. Comprehensive mutation analysis for congenital muscular dystrophy: a clinical PCRbased enrichment and next-generation sequencing panel. PLoS ONE. 8, e53083 (2013).
8. Morel, C. F. & Clarke, J. T. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease. Expert Opin. Biol. Ther. 9, 631-639 (2009).
9. Motwani, M., Banypersad, S., Woolfson, P. & Waldek, S. Enzyme replacement therapy improves cardiac features and severity of Fabry disease. Mol. Genet. Metab. 107, 197-202 (2012).
10. Ledbetter, D. H. Cytogenetic technology-genotype and phenotype. N. Engl. J. Med. 359, 1728-1730 (2008).
11. Ledbetter, D. H. Response to Saul and Moeschler "How best to use CGH arrays in the clinical setting". Genet. Med. 11, 371 (2009).
12. Schrauwen, I. et al. A sensitive and specific diagnostic test for hearing loss using a microdroplet PCR-based approach and next generation sequencing. Am. J. Med. Genet. A 61, 145-152 (2013).
13. Bamshad, M. J. et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nature Rev. Genet. 27, 745-755 (2011).
14. Francey, L. J. et al. Genome-wide SNP genotyping identifies the stereocilin (STRC) gene as a major contributor to pediatric bilateral sensorineural hearing impairment. Am. J. Med. Genet. A 158, 298-308 (2012).
15. Phylipsen, M. et al. Fine-tiling array CGH to improve diagnostics for and thalassemia rearrangements. Hum. Mutat. 33, 272-280 (2012).
16. ACMG Board of Directors. Points to consider in the clinical application of genomic sequencing. Genet. Med. 14, 759-761 (2012).
17. Johnston, J. J. et al. Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. Am. J. Hum. Genet. 91, 97-108 (2012).
18. The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56-65 (2012).
19. Fu, W. et al. Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature 493, 216-220 (2013).
20. Alasti, F., Van Camp, G. & Smith, R. J. H. Pendred syndrome/DFNB4. GeneReviews [online], http://www.ncbi.nlm.nih.gov/pubmed/20301640 (updated 20 Dec 2012).
21. Smith, R. J. H., Gurrola, J. G. & Kelley, P. M. OTOF-related deafness. GeneReviews [online], http://www.ncbi.nlm.nih.gov/pubmed/20301429 (updated 14 Jun 2011).
22. Köhler, S. et al. Clinical diagnostics in human genetics with semantic similarity searches in ontologies. Am. J. Hum. Genet. 85, 457-464 (2009).
23. Segal, M. How doctors think, and how software can help avoid cognitive errors in diagnosis. Acta Paediatr. 96, 1720-1722 (2007).
24. Green, R. C. et al. Exploring concordance and discordance for return of incidental findings from clinical sequencing. Genet. Med. 14, 405-410 (2012).
25. Teutsch, S. M. et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet. Med. 11, 3-14 (2009).
26. Palomaki, G. E., McClain, M. R., Melillo, S., Hampel, H. L. & Thibodeau, S. N. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet. Med. 11, 42-65 (2009).
27. Veenstra, D. L. et al. Improving efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. Genet. Med. 15, 14-34 (2013).
28. Share alike [editorial]. Nature 490, 143-144 (2012).
29. Baker M. One-stop shop for disease genes: NIH database integrates data from clinical genetic testing labs and literature. Nature 491, 171 (2012).
30. Quigley, F., Greene, M., O'Connor, D. & Kelly, F. A survey of the causes of sudden cardiac death in the under 35?year-age group. Ir. Med. J. 98, 232-235 (2005); erratum 98, 282 (2005).
31. Monserrat L et al. Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 50, 2399-2403 (2007).
32. Terryn. W. et al. Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy. Int. J. Cardiol. 15 Jul 2012 doi:10.1016/j.ijcard.2012.06.069.